647 related articles for article (PubMed ID: 30941119)
1. Anti-TNF Therapy in Spondyloarthritis and Related Diseases, Impact on the Immune System and Prediction of Treatment Responses.
Menegatti S; Bianchi E; Rogge L
Front Immunol; 2019; 10():382. PubMed ID: 30941119
[TBL] [Abstract][Full Text] [Related]
2. The current standard of care and the unmet needs for axial spondyloarthritis.
Noureldin B; Barkham N
Rheumatology (Oxford); 2018 Aug; 57(suppl_6):vi10-vi17. PubMed ID: 30445485
[TBL] [Abstract][Full Text] [Related]
3. Immune response profiling of patients with spondyloarthritis reveals signalling networks mediating TNF-blocker function in vivo.
Menegatti S; Guillemot V; Latis E; Yahia-Cherbal H; Mittermüller D; Rouilly V; Mascia E; Rosine N; Koturan S; Millot GA; Leloup C; Duffy D; Gleizes A; Hacein-Bey-Abina S; ; Sellam J; Berenbaum F; Miceli-Richard C; Dougados M; Bianchi E; Rogge L
Ann Rheum Dis; 2021 Apr; 80(4):475-486. PubMed ID: 33268443
[TBL] [Abstract][Full Text] [Related]
4. Biological therapies in the spondyloarthritides--the current state.
Braun J; Sieper J
Rheumatology (Oxford); 2004 Sep; 43(9):1072-84. PubMed ID: 15187239
[TBL] [Abstract][Full Text] [Related]
5. New evidence on the management of spondyloarthritis.
Sieper J; Poddubnyy D
Nat Rev Rheumatol; 2016 May; 12(5):282-95. PubMed ID: 27052489
[TBL] [Abstract][Full Text] [Related]
6. Drug Levels and Antibodies Against TNF-blockers in Spondyloarthritis and Rheumatoid Arthritis are Associated with the Activity but they do Not Predict it.
Padilla-Martínez EM; Romero-Sanchez C; Bello-Gualtero JM; Mesa-Betancourt AM; Bautista-Molano W; Valle-O R
Curr Rheumatol Rev; 2019; 15(4):329-335. PubMed ID: 31284866
[TBL] [Abstract][Full Text] [Related]
7. Risk of disease flare in spondyloarthritis patients after tapering tumor necrosis factor inhibitors: A meta-analysis and literature review.
Min HK; Kim HR; Lee SH; Nam B; Shin JH; Kim TH
Int Immunopharmacol; 2024 Jun; 134():112167. PubMed ID: 38754279
[TBL] [Abstract][Full Text] [Related]
8. Effect of Secukinumab and Tumor Necrosis Factor Inhibitors on Humoral Response to BNT162b2 mRNA Vaccine in Patients With Spondyloarthritis Compared to Immunocompetent Controls.
Eviatar T; Furer V; Polachek A; Zisman D; Peleg H; Elalouf O; Levartovsky D; Kaufman I; Broyde A; Haddad A; Feld J; Aassi M; Quebe-Fehling E; Alarcon I; Pel S; Paran D; Elkayam O
J Rheumatol; 2024 Apr; 51(4):415-422. PubMed ID: 37914221
[TBL] [Abstract][Full Text] [Related]
9. Predictive clinical-genetic model of long-term non-response to tumor necrosis factor-alpha inhibitor therapy in spondyloarthritis.
Polo Y La Borda J; Campos J; Sanz J; Andréu JL; Mulero J; Sánchez A
Int J Rheum Dis; 2019 Aug; 22(8):1529-1537. PubMed ID: 31119895
[TBL] [Abstract][Full Text] [Related]
10. [Immune-mediated inflammatory diseases in Germany : A cross-sectional analysis of comorbidities and pharmacotherapy].
Leipe J; Schmelz R; Riemekasten G; Thaçi D; Henes J; Schäkel K; Pinter A; Sticherling M; Wegner J; Fusco S; Linke M; Weber V; Manz KC; Bartz H; Roecken M; Schmidt S; Hoyer BF
Z Rheumatol; 2024 Apr; 83(3):200-209. PubMed ID: 36600054
[TBL] [Abstract][Full Text] [Related]
11. Impact of biological therapy on spondyloarthritis.
Maruotti N; Cantatore FP
Eur J Clin Pharmacol; 2014 Sep; 70(9):1021-7. PubMed ID: 24909930
[TBL] [Abstract][Full Text] [Related]
12. Emerging drugs for the treatment of axial and peripheral spondyloarthritis.
Braun J; Kiltz U; Heldmann F; Baraliakos X
Expert Opin Emerg Drugs; 2015 Mar; 20(1):1-14. PubMed ID: 25575936
[TBL] [Abstract][Full Text] [Related]
13. Anti-Drug Antibodies, Drug Levels, Interleukin-6 and Soluble TNF Receptors in Rheumatoid Arthritis Patients during the First 6 Months of Treatment with Adalimumab or Infliximab: A Descriptive Cohort Study.
Eng GP; Bouchelouche P; Bartels EM; Bliddal H; Bendtzen K; Stoltenberg M
PLoS One; 2016; 11(9):e0162316. PubMed ID: 27606615
[TBL] [Abstract][Full Text] [Related]
14. Cancer risk in patients with spondyloarthritis treated with TNF inhibitors: a collaborative study from the ARTIS and DANBIO registers.
Hellgren K; Dreyer L; Arkema EV; Glintborg B; Jacobsson LT; Kristensen LE; Feltelius N; Hetland ML; Askling J;
Ann Rheum Dis; 2017 Jan; 76(1):105-111. PubMed ID: 27147709
[TBL] [Abstract][Full Text] [Related]
15. Immunogenicity and autoimmunity during anti-TNF therapy.
Atzeni F; Talotta R; Salaffi F; Cassinotti A; Varisco V; Battellino M; Ardizzone S; Pace F; Sarzi-Puttini P
Autoimmun Rev; 2013 May; 12(7):703-8. PubMed ID: 23207283
[TBL] [Abstract][Full Text] [Related]
16. Absence of a classically activated macrophage cytokine signature in peripheral spondylarthritis, including psoriatic arthritis.
Vandooren B; Noordenbos T; Ambarus C; Krausz S; Cantaert T; Yeremenko N; Boumans M; Lutter R; Tak PP; Baeten D
Arthritis Rheum; 2009 Apr; 60(4):966-75. PubMed ID: 19333931
[TBL] [Abstract][Full Text] [Related]
17. mTOR Blockade by Rapamycin in Spondyloarthritis: Impact on Inflammation and New Bone Formation
Chen S; van Tok MN; Knaup VL; Kraal L; Pots D; Bartels L; Gravallese EM; Taurog JD; van de Sande M; van Duivenvoorde LM; Baeten DL
Front Immunol; 2019; 10():2344. PubMed ID: 32194539
[No Abstract] [Full Text] [Related]
18. Pharmacological management of axial spondyloarthritis in adults.
Toussirot E
Expert Opin Pharmacother; 2019 Aug; 20(12):1483-1491. PubMed ID: 31095430
[No Abstract] [Full Text] [Related]
19. Advances in the treatment of uveitis in patients with spondyloarthritis - is it the time for biologic therapy?
Mitulescu TC; Trandafir M; Dimăncescu MG; Ciuluvică RC; Popescu V; Predețeanu D; Istrate S; Voinea LM
Rom J Ophthalmol; 2018; 62(2):114-122. PubMed ID: 30206554
[TBL] [Abstract][Full Text] [Related]
20. Adverse effects of TNF inhibitors in SpA: are they different from RA?
Sampaio-Barros PD; van der Horst-Bruinsma IE
Best Pract Res Clin Rheumatol; 2014 Oct; 28(5):747-63. PubMed ID: 25488782
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
